# A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

> **NCT07083739** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** TQB3473 Tablets

## Key facts

- **NCT ID:** NCT07083739
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-09
- **Final completion:** 2028-03
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07083739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07083739, "A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT07083739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*